Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on September 16, 2014. The report addresses a significant legal development involving SIGA Technologies, Inc., specifically SIGA's voluntary Chapter 11 bankruptcy filing following a Delaware Court of Chancery ruling in PharmAthene's favor regarding lost profits for the smallpox antiviral Tecovirimat.
Key Financial Metrics and Legal Exposure
- Expected Damages: SIGA estimates the potential judgment against it to be substantial, ranging from at least $180 million to as much as $232 million or more, inclusive of pre-judgment interest and professional fees.
- Revenue Context: SIGA expects to continue its contract with BARDA, with eligibility for up to an additional $211.5 million in revenue on top of the $198 million already received.
- Liquidity Status: SIGA has publicly stated it does not currently possess sufficient cash to satisfy the potential award.
- Enforcement Status: PharmAthene is automatically stayed from taking enforcement actions due to SIGA's bankruptcy filing.
Material Changes and Developments
The primary material change is SIGA's Chapter 11 bankruptcy filing on September 16, 2014. This event fundamentally alters the collection landscape for the damages awarded by the Delaware Court of Chancery on August 8, 2014. While the Chancery Court found PharmAthene entitled to lump sum expectation damages, interest, and fees, the specific dollar amount has not yet been finalized by the court. The bankruptcy filing places SIGA's assets under protection for creditors and subjects any potential payment to the discretion of the Bankruptcy Court.
Outlook, Risks, and Contingencies
- Uncertainty of Payment: There are no assurances regarding whether or when PharmAthene will receive any payments. The final award amount remains subject to calculation, approval, and potential appeal by SIGA to the Delaware Supreme Court.
- Bankruptcy Proceedings: The legal findings in Delaware are separate from the New York bankruptcy proceedings. Any payment by SIGA will be contingent on decisions made by the Bankruptcy Court.
- Appeal Risk: The Chancery Court's decision could be reversed, remanded, or otherwise changed upon appeal.
Investor Verification Checklist
- Verify the final dollar amount of damages once calculated and approved by the Delaware Court of Chancery.
- Monitor the status of SIGA's Chapter 11 bankruptcy proceedings in the Southern District of New York to assess the likelihood of creditor repayment.
- Track any appeals filed by SIGA to the Delaware Supreme Court that could alter the liability amount.
- Confirm SIGA's actual cash position and asset liquidation plans as disclosed in subsequent bankruptcy filings.